Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,080
Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock
Earnings Preview: REGN to Report Financial Results Pre-market on October 31
$Regeneron Pharmaceuticals(REGN.US)$ is scheduled to release its financial results pre-market on October 31 ET. Earnings PreviewAnalysts estimate $Regeneron Pharmaceuticals(REGN.US)$ to post revenue
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Regeneron Pharmaceuticals Analyst Ratings
Lilly's Ebglyss Shown to Be Effective in Former Dupixent Users
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,260
Sanofi Posts Q3 Revenue Beat as Dupixent Sales Jump
Evercore Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,175
Regeneron Pharma Is Maintained at Outperform by Evercore ISI Group
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,800 Today
Regeneron, Sanofi Report Dupixent 'Significantly' Reduced Itch, Hive Activity in Phase 3 Study for CSU
Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,250
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $1,080 to $1,242
Regeneron And Sanofi To Present Phase 3 LIBERTY-CUPID Study C Study Data Evaluating Dupixent; Says Dupixent Reduced Itch And Hive Activity From Baseline, 41% Of Patients Achieved Well-Controlled Disease Status
Express News | Sanofi/Regeneron: Announce More Positive Data for Dupixent
Express News | Regeneron Pharmaceuticals Inc : JP Morgan Cuts Target Price to $1150 From $1200
Dupixent (Dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
A Closer Look at 23 Analyst Recommendations For Regeneron Pharmaceuticals
Amgen Gears Up to Report Q3 Earnings: Here's What to Expect